FDA approves label expansion for Shire’s HAE drug Cinryze

This article was originally published here

Shire has secured a label expansion from the US Food and Drug Administration (FDA) for its hereditary angioedema (HAE) therapy Cinryze to help prevent angioedema attacks in HAE-affected children, aged 6 years and older.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply